How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology

Anticancer Research

Volumn 29, Issue 9, 2009, Pages 3675-3684

  Vieth, Reinhold ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Control theory; Enzyme kinetics; Pancreas; Prostate cancer; Review; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; VITAMIN D;

CANCER PREVENTION; CANCER RISK; CONFERENCE PAPER; DIET SUPPLEMENTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SUMMER; ULTRAVIOLET RADIATION; VITAMIN D METABOLISM; VITAMIN INTAKE;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; HUMANS; NEOPLASMS; STEROID HYDROXYLASES; VITAMIN D;

EID: 68549130609     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. IARC Working Group on Vitamin D: Vitamin D and Cancer. Report number 5. Geneva, Switzerland, WHO Press, 2008.
2. Bouillon R, Moody T, Sporn M, Barrett JC and Norman AW: NIH deltanoids meeting on Vitamin D and cancer. Conclusion and strategic options. J Steroid Biochem Mol Biol 97: 3-5, 2005. (Pubitemid 41546207)
3. Grant WB: An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 94: 1867-1875, 2002.
4. John EM, Dreon DM, Koo J and Schwartz GG: Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol 59-90: 549-552, 2004. (Pubitemid 38844346)
5. Giovannucci E: The epidemiology of vitamin D and cancer incidence and mortality: A review (United States). Cancer Causes Control 16: 83-95, 2005. (Pubitemid 40691207)
6. Neale RE, Youlden DR, Krnjacki L, Kimlin MG and van der Pols JC: Latitude variation in pancreatic cancer mortality in Australia. Pancreas 38: 387-390, 2009.
7. Tuohimaa P, Lyakhovich A, Aksenov N, Pennanen P, Syvala H, Lou YR, Ahonen M, Hasan T, Pasanen P, Blauer M, Manninen T, Miettinen S, Vilja P and Ylikomi T: Vitamin D and prostate cancer. J Steroid Biochem Mol Biol 76: 125-134, 2001.
8. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM and Hayes RB: Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100: 796-804, 2008. (Pubitemid 351809669)
9. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J and Albanes D: A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 66: 10213-10219, 2006. (Pubitemid 44672077)
10. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW and Silverman DT: Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res 69: 1439-1447, 2009.
11. Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjonneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kroger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larranaga N, Gonzalez CA, Arguelles MV, Sanchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E and Key TJ: Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 169: 1223-1232, 2009.
12. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M and Hakama M: Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108: 104-108, 2004. (Pubitemid 37444451)
13. Vieth R: Enzyme kinetics hypothesis to explain the U-shaped risk curve for prostate cancer vs. 25-hydroxyvitamin D in nordic countries. Int J Cancer 111: 468, 2004. (Pubitemid 38998832)
14. John EM, Schwartz GG, Koo J, Van Den BD and Ingles SA: Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 65: 5470-5479, 2005. (Pubitemid 40827360)
15. Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, and Strange RC: Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 85: 1504-1509, 2001. (Pubitemid 34001581)
16. Schwartz GG and Hanchette CL: UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 17: 1091-1101, 2006.
17. Tretli S, Hernes E, Berg JP, Hestvik UE and Robsahm TE: Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 100: 450-454, 2009.
18. 3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 15: 149-158, 2004. (Pubitemid 38445361)
19. Vieth R, Choo R, Deboer L, Danjoux C, Morton G and Klotz L: Rise in Prostate-Specific Antigen in Men with Untreated Low-Grade Prostate Cancer Is Slower During Spring-Summer. Am J Ther 13: 394-399, 2006. (Pubitemid 44435010)
20. Woo TC, Choo R, Jamieson M, Chander S and Vieth R: Pilot Study: Potential Role of Vitamin D (Cholecalciferol) in Patients With PSA Relapse After Definitive Therapy. Nutr Cancer 51: 32-36, 2005. (Pubitemid 40365979)
21. Barreto AM, Schwartz GG, Woodruff R and Cramer SD: 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9: 265-270, 2000.
22. 3. Carcinogenesis 25: 1015-1026, 2004. (Pubitemid 38898637)
23. 3 production. American J Physiology 258: E780-89, 1990. (Pubitemid 20179439)
24. Jagacinsk RJ and Flach J: Control Theory for Humans: Quantitative Approaches to Modeling Performance. Lawrence Erlbaum Associates, Mahwah, New Jersey. 2003.
25. Vieth R, Milojevic S and Peltekova V: Improved cholecalciferol nutrition in rats is noncalcemic, suppresses parathyroid hormone and increases responsiveness to 1, 25-dihydroxycholecalciferol. J Nutr 130: 578-584, 2000. (Pubitemid 30118074)
26. 3 in rats. Nutrition Research 15(5): 725-731, 1995.
27. 3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 93: 3430-3435, 2008.
28. 3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 93: 3430-3435, 2008.
29. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF and Chen TC: The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by paramyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25: 967-971, 2004. (Pubitemid 38898635)
30. Vieth R: The Pharmacology of Vitamin D, Including Fortification Strategies. In: Vitamin D. Feldman D, Glorieux F, and Pike JW (eds). New York, Elsevier, pp. 995-1015, 2005.
31. Cross HS, Kallay E, Farhan H, Weiland T and Manhardt T: Regulation of extrarenal vitamin D metabolism as a tool for colon and prostate cancer prevention. Recent Results Cancer Res 164: 413-425, 2003.
32. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW and Pinkel D: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25: 144-146, 2000. (Pubitemid 30394982)
33. Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M, Inoue H and Mori M: Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol 15: 236-241, 2004. (Pubitemid 38262621)
34. Farhan H, Wahala K and Cross HS: Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 54: 423-429, 2003. (Pubitemid 36555765)
35. Chen TC, Holick MF, Lokeshwar BL, Burnstein KL and Schwartz GG: Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res 164: 273-88.: 273-288, 2003.
36. 3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 92: 131-141, 2004. (Pubitemid 39535854)
37. Chen TC: 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. Anticancer Res 28: 2015-2017, 2008.
38. Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D and Peehl DM: Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol 221: 67-74, 2004. (Pubitemid 38829724)
39. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF and Chen TC: 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81: 135-140, 2002.
40. Hsu JY, Feldman D, McNeal JE and Peehl DM: Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61: 2852-2856, 2001. (Pubitemid 32691924)
41. Harris SS and Dawson-Hughes B: Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 67: 1232-1236, 1998.
42. Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD and Reid IR: The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr 86: 959-964, 2007.
43. Kimlin MG: Geographic location and vitamin D synthesis. Mol Aspects Med 29: 453-461, 2008.
44. Vieth R: Enzyme kinetics hypothesis to explain the U-shaped risk curve for prostate cancer vs. 25-hydroxyvitamin D in Nordic countries. Int J Cancer 111: 468, 2004. (Pubitemid 38998832)
45. 3 24-hydroxylase messenger RNA for degradation: implications in anticancer activity. Mol Cancer Ther 6: 3131-3138, 2007.
46. Knight JA, Lesosky M, Barnett H, Raboud JM and Vieth R: Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16: 422-429, 2007. (Pubitemid 46548644)
47. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF and Chen TC: The prostate 25-hydroxyvitamin D-1{alpha}-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004. (Pubitemid 38898635)
48. Frost HM: Bone "mass" and the "mechanostat": a proposal. Anat Rec 219: 1-9, 1987.
49. Turner CH: Toward a mathematical description of bone biology: the principle of cellular accommodation. Calcif Tissue Int 65: 466-471, 1999.
50. Trivedi DP, Doll R, and Khaw KT: Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326: 469-475, 2003. (Pubitemid 36269626)
51. Heikinheimo RJ, Haavisto MV, Harju EJ, Inkovaara JA, Kaarela RH, KolhoLA, and Rajala SA: Serum vitamin D level after an annual intramuscular injection of ergocalciferol. Calcified Tissue International 49(Suppl): S87, 1991.
52. Tang BM, Eslick GD, Nowson C, Smith C, and Bensoussan A: Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370: 657-666, 2007. (Pubitemid 47285316)
53. Bischoff-Ferrari HA: How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 18: 401-407, 2007. (Pubitemid 46354929)
54. Vieth R: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69: 842-856, 1999. (Pubitemid 29205056)
55. Buxton ILO: Pharmacokinetics And Pharmacodynamics: The Dynamics Of Drug Absorption, Distribution, Action, And Elimination. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. Brunton LL (ed.). McGraw-Hill, Medical Publishing Division, New York, pp. 1-41, 2006.
56. Vieth R: Vitamin D toxicity, policy, and science. J Bone Miner Res 22(Suppl 2): V64-V68, 2007.
57. 3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 93: 3430-3435, 2008.
58. 3 in humans. J Clin Endocrinol Metab 89: 5387-5391, 2004. (Pubitemid 39518413)
59. Kruk ME and Schwalbe N: The relation between intermittent dosing and adherence: preliminary insights. Clin Ther 28: 1989-1995, 2006.
60. Rossini M, Viapiana O, Gatti D, James G, Girardello S and Adami S: The long term correction of vitamin D deficiency: comparison between different treatments with vitamin D in clinical practice. Minerva Med 96: 1-7, 2005.
61. Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA and Fuchs CS: Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev 15: 1688-1695, 2006. (Pubitemid 44497105)